ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
BioHarvest Sciences Inc (QB)

BioHarvest Sciences Inc (QB) (CNVCF)

5.34
0.00
( 0.00% )
Updated: 14:21:32

Professional-Grade Tools, for Individual Investors.

CNVCF News

Official News Only

CNVCF Discussion

View Posts
happyglass happyglass 4 months ago
The reverse split is timely if they are looking to uplist. With cannabis being shifted to schedule 3 I see this as an excellent move. I hope the market sees what I see
👍️0
happyglass happyglass 4 months ago
Thank you for the update
👍️0
Renee Renee 4 months ago
CNVCF: effective June 3,2024 a one for 35 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
👍️0
happyglass happyglass 5 months ago
I prefer they walk before they run. Pleased with the improvements. Get the share price up organically not through consolidation.
https://markets.qtrade.ca/news/story?t=iKXJizM-dSY,RBgdWBB-F545YeUB8Z65joEjuF4_Nb5o&article=4e71cccf72d47418#4e71cccf72d47418
👍️0
happyglass happyglass 6 months ago
So happy to be funding the enlightenment. Hopefully others will come along too, it is getting lonesome lol!
👍️0
happyglass happyglass 9 months ago
They have positioned themselves well. Pivoted to their other products while the bumps on the path to cannabis legalization get smoothed out. Very eager for the future
👍️0
moneeymaker moneeymaker 9 months ago
It will be cash flow positive this quarter. This is very rare for a micro cap company.
👍️ 1
happyglass happyglass 10 months ago
While everyone got shaken out of the cannabis space, the good companies just kept on working
https://markets.qtrade.ca/news/story?t=iKXJizM-dSY,RBgdWBB-F545YeQE_ZC_i3ESEqGOaXkD&article=56fb7bf8e99d1d77#56fb7bf8e99d1d77
👍️0
happyglass happyglass 2 years ago
New update they have been very busy
👍️0
happyglass happyglass 2 years ago
I like to back companies that do what they say they will
Royal Emerald Pharmaceuticals is a #California-based U.S. DEA & FDA-registered manufacturer/supplier of non-addictive #cannabis products being developed for medical, scientific & research purposes. We're extremely proud to be partnering with them!#biotech https://t.co/idppATIy9E— BioHarvest Sciences Inc. (@BioHarvestBHSC) November 16, 2022
👍️0
Thugmuffin Thugmuffin 2 years ago
$CNVCF BioHarvest Sciences Inc. Announces Live Quarterly Shareholder Update Event July 7, 2022, at 2:00 PM ETPress Release | 06/24/2022

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 24, 2022) - BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or "the Company") invites its shareholders and the general public to join a Live Video Conference ("Webinar") on Thursday, July 7, 2022, at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time).

BioHarvest Sciences CEO Ilan Sobel will host the event, which will include coverage of Q2 sales results and a detailed progress update on the 2022 Growth Priorities, with specific focus on the VINIA scale-up progress in the USA and on the Company's Cannabis market entry strategy into North America.

"We have reached the midpoint of 2022, which will be remembered as a transformative year in BioHarvest Science's growth," states CEO Ilan Sobel, adding "This year we have already made key additions to our leadership team and reached major scientific milestones - I am very excited to discuss our progress on the VINIA USA scale-up, to provide a high level update on strategic partnership discussions with key players in the North American Cannabis landscape, and to share my thoughts with our Bioharvest shareholder partners on how our disruptive platform technology will reshape the future of the Cannabis industry in North America."

The presentation will be approximately 45 minutes, followed by a live question and answer session. All shareholders, media, and interested investors are welcome to join. All registrants will be emailed a recording of the session. Any questions regarding the event can be sent to justin@bioharvest.com.

Register for free at: Q2 2022 BioHarvest Sciences Inc. Shareholder Update | BioHarvest Sciences (livestorm.co)

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6168/128834_9fd6d70f6470694a_001full.jpg

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit:www.bioharvest.com.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Facebook Twitter Linkedin Youtube

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis, whether in North America or other global markets. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion are subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and/or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/128834
👍️0
McMagyar McMagyar 2 years ago
Good hire
Target $4 / share .. 24 months
👍️0
Thugmuffin Thugmuffin 2 years ago
$CNVCF BioHarvest Sciences Hires Dr. Brian S. Cornblatt as Chief Medical OfficerPress Release | 05/31/2022

Vancouver, British Columbia, and Rehovot, Israel--(Newsfile Corp. - May 31, 2022) - BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") has hired Dr. Brian S. Cornblatt as its Chief Medical Officer, marking a significant milestone in the Company's route for the development of next generation therapeutic solutions including botanical drugs.

Dr. Cornblatt has served as Director of Consumer Clinical Research and Science and as Medical Director at Nutramax Laboratories Consumer Care, Inc. In this role Dr. Cornblatt developed novel nutraceutical formulations, designed both in vitro and clinical studies in support of products, and summarized both supporting laboratory and clinical research for healthcare workers and consumers. His most recent development has been a novel line of products (and 18 related clinical trials) which deliver the essential ingredients needed to support the production of sulforaphane, a phytochemical with many emerging indications. Dr. Cornblatt is also the inventor of three issued patents and four pending provisional patents focused on plant-based bioactive compounds and health promotion.

Prior to moving to Nutramax Laboratories in 2010, Dr. Cornblatt was the Scientific Director and Developer of the Catholic Health Initiatives' (CHI) Center for Translational Research (CTR), a combined molecular research laboratory, national biorepository, and diagnostics laboratory. The CTR supported research initiatives throughout CHI's forty Oncology centers.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6168/125931_9eab594d94ac6b7c_002full.jpg

Dr. Brian S. Cornblatt

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6168/125931_9eab594d94ac6b7c_002full.jpg

Dr. Cornblatt is a Johns Hopkins University School of Medicine Graduate with a Ph.D. in Pharmacology and Molecular Sciences and a postdoctoral fellowship from the Johns Hopkins Bloomberg School of Public Health, Environmental Health Sciences Division of Toxicology.

"We are delighted to welcome Dr. Cornblatt to the leadership team at BioHarvest at a time of transition and growth for us," said BioHarvest CEO Ilan Sobel. "He will help us lead the charge as we take steps to actively expand our line up of clinically based nutraceutical products and move into medicinal prescription products with our polyphenol-based products and Cannabis product line up."

Dr. Cornblatt said "I am excited about the opportunities that BioHarvest has in the medicinal space based on the CELLicitation™ technology. Some of the existing products can already form a potential for future botanical drugs and I am looking at expanding the indications for which unique products like VINIA® can be used. I look forward to working with the capable R&D team to bring to the world unique, clinically based therapeutic solutions."

BioHarvest is seeking to receive authorization in Israel to produce Cannabis for commercial purposes and is also looking to expand production facilities to North America. BioHarvest recently announced that it has produced a meaningful amount (10 kilograms) of full-spectrum Cannabis biomass at a commercial scale without growing the plant itself. (For full illustration, Watch this video or visit https://bioharvest.com. It is the first time that any group - in either industry or academia - has successfully produced meaningful quantities of full-spectrum Cannabis biomass without growing the plant itself. The Cannabis biomass is not genetically modified and was produced using the Company's proprietary BioFarming technology platform, which grows plant cells in their natural structure in proprietary bioreactors. The company has also recently (May 12) unveiled the profile of its unique Cannabis composition. It contains major and minor cannabinoids as well as terpenes.

BioHarvest has a market capitalization of approximately CAD$131M and has raised over CAD$ 58M to date. The Company holds unique patented technology that allows it to produce a unique grade of full spectrum, consistent, and clean Cannabis biomass in industrial-scale bioreactors with manufacturing costs which are significantly below industry benchmarks. Its offering will consist of multiple unique Cannabis compositions selected based on specific indications and B2B customer requirements.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.

Ilan Sobel, Chief Executive Officer

For further information, please contact:
Investor Relations
Phone: 778.686.3855
Email: info@bioharvest.com

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. There is no assurance that the ability to produce a commercial sized biomass will result in the Company entering into commercial production of Cannabis. Clinical trials are subject to risks of significant cost overruns and lengthy delays with no assurance they will confirm desired results. Even where desired results are obtained government approvals for treatments take considerable time and cannot be guaranteed. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. Delays and cost overruns may result in delays achieving our objectives. Obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured. There is no assurance the company will successfully expand its lineup of nutraceutical products or move into medical prescription products. Successful completion of these objectives will require additional financing, successful marketing initiatives, and certifications which are subject to uncertainty. In addition, prescription drug products require clinical trials which may be lengthy and expensive and have uncertain results. There is no assurance that the company will be approved for commercial Cannabis production in Israel or elsewhere. Obtaining such approvals is subject to many risks and uncertainties, in addition to the need for financing, including potential delays, unexpected changes in requirements and unexpected failure to meet requirements.

All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/125931
👍️0
Farmpride Farmpride 2 years ago
I sure would like to see some photos of the shop, the vats , please…even a nice “walk thru” video of our production facilities would be so welcome…??

Al / Farmpride
👍️0
McMagyar McMagyar 2 years ago
The word is getting out about Vinia for the heart..
..
👍️0
Thugmuffin Thugmuffin 2 years ago
$CNVCF BioHarvest Sciences Unveils Profile of Unique Cannabis CompositionPress Release | 05/12/2022

Full spectrum profile to include major and minor Cannabinoids as well as Terpenes
Unique trichome structure provides for potentially higher solubility and bio-availability
With Trichomes representing 93% of the Cannabis biomass produced using the proprietary Bio-Plant CELLicitation™ technology, taste bitterness is significantly reduced

Vancouver, Canada, and Rehovot, Israel--(Newsfile Corp. - May 12, 2022) - BioHarvest Sciences Inc. the (CSE: BHSC) ("BioHarvest" or the "company") today unveiled the composition profile of its full-spectrum Cannabis produced in large-scale industrial bioreactors based on its proprietary Bio-Plant CELLicitation™ platform technology.

On December 8th, 2021, BHSC became the first company ever to announce that it could produce Cannabis biomass without growing the plant itself. The revealing of the unique composition profile of its first product comes as BioHarvest gears up for potential Cannabis commercialization - optimizing the manufacturing process, perfecting measurement techniques, transitioning the 2-ton/year facility to Cannabis and applying for the necessary regulatory approvals.

Reliable testing and measurements demonstrate that the composition profile includes the Cannabinoids THC, CBD, CBG, THCV, CBDV and CBC, as well as the Terpenes Beta-caryophyllene, Beta-panasinsene and Selina. While other minor Cannabinoids are present, their identity determination requires further work on the measurement techniques as the current conventional ones are not advanced enough to deal with such a distinctive Cannabinoids profile. The profile and ratio between the various Cannabinoids found in BioHarvest's product is unique and sets a path for both potential patentability and applicability to address medical indications such as ADHD, pain management and anxiety. For further protection of BioHarvest's IP and to secure patentability, more quantitative information about the profile will be revealed before September 15th, 2022. In the interim, the company confirms with certainty the significance of THC, CBD and CBG quantities inside the unique Cannabis composition.

"These achievements are remarkable and demonstrate the ability to produce unique and consistent Cannabis compositions that would have been impossible using conventional agriculture," said Prof. Zohar Kerem, Head of the Food Chemistry Labs of the Robert H. Smith Faculty of Agriculture, Food and Environment of the Hebrew University of Jerusalem. "I have been closely watching the application of BioHarvest's Bio-Plant CELLicitation™ technology to Cannabis, and I am confident that advanced analysis techniques will become available soon to further unveil the Cannabinoids richness of the unique BioHarvest's compositions."

One of the special characteristics of this Cannabis product is that it is made of trichomes representing 93% of the biomass. Trichomes are the plant's natural "mini-factories" that produce the active Cannabis ingredients (Cannabinoids, terpenes and other phytochemicals). Unlike conventional Cannabis products where a significant part of the biomass includes other parts of the flower which have a bitter taste, BioHarvest's product is primarily composed of trichomes. This significant reduction of bitterness renders the product easier to integrate in food and beverage applications.

Moreover, the unique conformation of our trichomes (amalgamated in a coral shape structure) may provide for enhanced solubility and bio-availability of the product. This would allow administration of lower doses to achieve the same desired effects, which would otherwise require a higher quantity in the case of conventionally cultivated Cannabis products.

"Our consistent, clean and efficacious Cannabis, produced with the highest ESG credentials and capital efficiency, has received a significant boost with the latest conclusive composition profile information," said CEO Ilan Sobel. "This rich full-spectrum combination of Cannabinoids and Terpenes with unique ratios is very promising for addressing medical conditions otherwise treated by synthetic drugs with significant negative side effects. The reduced bitterness taste and the potential improved solubility of our products amount to a game-changer for integration of full-spectrum Cannabis into the food & beverage industry."

BioHarvest plans to bring its first Cannabis products to market in 2022 and will be converting the current VINIA® 2-tons/year facility in Rehovot, Israel to produce Cannabis. This is happening as a result of the transition of all VINIA ® manufacturing to the new 20-ton/year facility in Yavneh, Israel.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Twitter
Facebook
LinkedIn
YouTube

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. Clinical trials are subject to risks of significant cost overruns and lengthy delays with no assurance they will confirm desired results. Even where desired results are obtained government approvals for treatments take considerable time and cannot be guaranteed. There is no assurance the BioFarming technology will make a significant impact on multiple verticals of life -science based businesses in general or in the bio-space industry. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured. There is no assurance of patentability of the Company's products. Obtaining patents is a lengthy process subject to many uncertainties. The ability of the Company's product to address medical indications in a manner different from other Cannabis products can only be determined after the process of clinical trials, the outcome of which cannot be assured.

In particular there is no assurance the company will obtain a production license or bring its first Cannabis products to market in 2022.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/123755
👍️0
Thugmuffin Thugmuffin 3 years ago
$CNVCF Bioharvest Sciences Inc. Successfully Completes Cannabis R&D ProgramPress Release | 03/23/2022

Now producing Cannabis biomass in large scale industrial bioreactors under the current R&D license.
Commencing the process of transitioning the current Israeli Cannabis R&D license to a production license.

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 23, 2022) - BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") today announced that it has produced Cannabis Biomass in large scale industrial bioreactors, which represents the completion of the Company's Cannabis R&D program.

On December 8th, 2021, BHSC became the first company ever to announce that it could produce Cannabis biomass without growing the plant itself. Building on that breakthrough, the Company has made significant progress, and has now produced Cannabis in large scale industrial bioreactors, marking the start of the transition to commercial scale manufacturing. To that end, the Company has commenced the process to obtain a production license in Israel for its Cannabis products to complement the R&D license it has used to date for the Cannabis development program.

Dr. Yochi Hagay, CTO, said "I am elated and proud of this achievement. The R&D team has relentlessly pursued this moment, which marks a new era for the Cannabis industry. Our proprietary and unique amalgamated trichome structure has proven resistant to shear forces applied during the cell growth process in liquid media and it will demonstrate more advantages when it comes to the medicinal application of our products. I have never doubted our ability to use our CELLicitation technology to produce Cannabis without the need to grow the plant itself and we have broken biological barriers to grow high performance trichomes in liquid suspension. We are now ready to bring our first unique Cannabis compositions to the world. We will of course continue to invest in Cannabis R&D to add more Cannabis products to the portfolio, appreciate the IP assets and drive even further manufacturing efficiencies."

BioHarvest plans to bring its first Cannabis products to market in 2022 and will be converting the current VINIA® 2 tons/year facility in Rehovot, Israel to produce Cannabis. This is happening in conjunction with the transition of all VINIA ® manufacturing to the new 20 tons/year facility in Yavneh, Israel, which will support the scaling of successful sales of VINIA® in the US and beyond.

Ilan Sobel, CEO, states "Our unprecedented achievements present a great opportunity for the Cannabis industry. Consistent, clean, and efficacious Cannabis that is produced with the highest ESG credentials and capital efficiency with significantly lower manufacturing costs is the revolution this industry needs to gain further market traction and trust by the regulators worldwide. Our CELLicitation platform technology is a true market disruptor, cementing BioHarvest's position as a leader in plant cellular biology. With the completion of the initial Cannabis R&D program, more focus can now be applied towards achieving the desired scale for our two business verticals, Polyphenols/Antioxidants and Cannabis."

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Twitter
Facebook
LinkedIn
YouTube

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. Clinical trials are subject to risks of significant cost overruns and lengthy delays with no assurance they will confirm desired results. Even where desired results are obtained government approvals for treatments take considerable time and cannot be guaranteed. There is no assurance the BioFarming technology will make a significant impact on multiple verticals of life -science based businesses in general or in the bio-space industry. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured.

In particular there is no assurance the company will obtain a production license or bring its first Cannabis products to market in 2022.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.
👍️0
McMagyar McMagyar 3 years ago
Sorry my math sucks
They are expanding from 2 to 20 multiple times a year.. so 10 times increase multiple times a year..

Company right now around 120 mil

I couldn’t tell you sales numbers but IMO their cannabis operation alone could support a 120 mil Valuation..

And Vinia is going to be wildly succesful
👍️0
McMagyar McMagyar 3 years ago
My timing is horrible sometimes.. so don’t listen to me making money on stocks.. the biggest benefit anyone can get is taking this product…
If I had my Trivesta up and running this would be a stock evEry Christian would buy at least three shares in..
Anavex and Bioharvest.. Annovis too..
Those would be my first Trivesta!

Bioharvest is expanding their capacity not just 20 times.. they are expanding their capacity 20 times multiple times a year!

It’s a turning point
👍️0
happyglass happyglass 3 years ago
That is what attracted me to this company. They are already producing in large quantity. Now they are expanding operations. To me it is the right product at the right time
👍️0
McMagyar McMagyar 3 years ago
Bioharvest pumping out extraordinary
Resveratol..
👍️0
Farmpride Farmpride 3 years ago
I was just going over old online news… finding postings back to 2008 showing “we” where ready to build plants and produce in …”the next quarter”. Here, and looking forward again.. to a new quarter. (2014 in New York?)
I love this idea, WE could become the number one grower / producer of so many products. Is ideas like this that will feed millions, not just printed or formed “crap”, but real food…just …when ? One other Prayer over our future.. let’s not be sold on only growing HIGH DOLLAR PRODUCT. The world needs high quality foods, at common food prices…not just pricy “space-food” or more overpriced CBD oil…excetera . ….so….WHEN?
👍️0
AskMuncher AskMuncher 3 years ago
$CNVCF BioHarvest Sciences Inc. Engages Thunder11 as a Public Relations Agency of Record
Press Release | 02/10/2022
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - February 10, 2022) - BioHarvest Sciences Inc. (CSE: BHSC) (OTC PINK: CNVCF) (FSE:8MV) ("BioHarvest" or "the Company") a fast-growing Biotech firm listed on the Canadian Securities Exchange, has engaged the award winning New York City-based communications firm Thunder11 for Public Relations services.

Thunder11, which has specializations in technology, healthcare, and public affairs, will be involved in raising BioHarvest's profile with media relations, partners, and other influential audiences. BioHarvest joins a roster of Thunder11 clients which over the years has included some of the world's leading technology companies and healthcare organizations.

In January 2022, BioHarvest announced its plan to build a production facility in Canada as part of the global expansion of its Cannabis vertical. BioHarvest also recently announced it has also moved its production of full-spectrum Cannabis biomass to industrial scale bioreactors, a critical final step in ensuring adequate production levels for commercialization. This full spectrum, fertiliser free, non-genetically modified biomass is based on the company's proprietary BioFarming technology.

"We are delighted to be working with BioHarvest to tell the world the story of their breathtaking innovations, including the production of Cannabis without growing the plant," said Thunder11 Managing Partner Dan Perry. "Such innovation is not only disruptive in a good way but has tremendous potential for humanity's health and wellness as well as global sustainability."

Thunder11 offers its clients a broad range of capabilities from messaging and brand identity to thought leadership, content creation, crisis and issues management and communications and sales force training. The firm was recognized in 2019 as "Boutique PR Firm of the Year" at the Platinum PR Awards and in 2020 was named to the Agency Elite Top 100 list of leading communications agencies.

Thunder11 is led by Senior Partner Marco Greenberg, a former managing director at Burson-Marsteller and author of the 2020 Wall Street Journal bestseller "Primitive: Tapping the Primal Drive That Powers the World's Most Successful People." Marco's first PR firm worked with Akamai Technologies several years from inception through IPO. He later helped lead communications for Datto through their acquisition by Vista Equity Partners, among many other fortune 500 companies.

Greenberg co-founded Thunder11 in 2007 with Liel Leibovitz, a former NYU communications professor, host of the award-winning podcast "Unorthodox," and an author of several books including "A Broken Hallelujah: Rock and Roll, Redemption, and the Life of Leonard Cohen." Tel Aviv-based Perry was the former top editor of the Associated Press in Europe, Africa and the Middle East and the author of several books on Israel. The firm's leadership includes SVP Client Relations Ryan Birchmeier, who leads the BioHarvest account.

BioHarvest joins the many companies Thunder11 has represented, from small to large cap and Fortune 500 organizations, as well as universities, major regional healthcare systems, tech and biotech startups, venture capital firms and public affairs campaigns. In recent years, several Thunder11 clients have been named to Fast Company's Most Innovative Companies and World Changing Ideas lists and TIME's Best Inventions. Its clients have appeared everywhere from SXSW to CES from Web Summit to Aspen Ideas Festival, and among other prestigious stages around the world.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Twitter
Facebook
LinkedIn
YouTube

Forward-Looking Statements

Information set forth in this news release includes forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.
👍️0
AskMuncher AskMuncher 3 years ago
$CNVCF BioHarvest Sciences Inc. Plans to Build a Production Facility in Ontario to Serve the Canadian Market with Unique Cannabis Products
Press Release | 01/20/2022
Vancouver, British Columbia, and Rehovot, Israel--(Newsfile Corp. - January 20, 2022) - BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") has announced its plan to build a production facility in Canada, as part of the next phase in the global expansion of its Cannabis vertical. To that end, the Company is exploring opportunities to acquire an existing licensed facility or a Licensed Producer (LP), which would enable the Company to use its BioFarming technology to produce and then sell unique cannabis products into the Canadian market.

The Company is pleased to announce that it has also moved its production of full-spectrum Cannabis biomass to industrial scale bioreactors, which is a critical final step in ensuring adequate production levels for commercialization. This full spectrum, pesticide free, non-genetically modified biomass is based on the Company's proprietary BioFarming technology that produces Cannabis without growing the plant itself.

Following the news release on December 8, 2021, where the Company announced that it was the first to produce a significant amount of full spectrum, non GMO Cannabis biomass without growing the Cannabis plant itself, the Company has moved swiftly towards the final stage of the development program by now growing the Trichome cells in industrial scale bioreactors. The Trichome cells contain Cannabinoids such as CBD, THC, as well as other compounds that grow naturally in the Cannabis plant. This stage successfully tested the resilience of BioHarvest's proprietary "amalgamated Trichome cells" against the shear forces generated by the large bioreactor's liquid media motion. These amalgamated Trichomes have a coral shaped structure and have a density of up to 200 times greater than the conventional agriculture case. To view the first video footage of our Cannabis biomass, visit www.bioharvest.com/investors.

Ilan Sobel, CEO of BioHarvest, said, "Our BioFarming technology not only enables the production of full-spectrum Cannabis without growing the plant but also creates unique new patentable and consistent compositions that will have corresponding human utility value. I am excited about the opportunity to bring such unique Cannabis solutions to the Canadian market by building a local production facility in Canada. To that end, we have started the engagement for finding an adequate facility and/or acquiring an existing LP who has the appropriate licenses."

BioHarvest is asking those LP's who are interested in a collaborative agreement regarding this announcement to send requests to partnership@bioharvest.com.

All interested media and investors are invited to attend an 'Introduction to BioHarvest' webinar on January 26, at 11 am PST. The event will include a live Question and Answer session. Please register here: https://app.livestorm.co/st-financial/introduction-to-bioharvest?type=detailed

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Twitter
Facebook
LinkedIn
YouTube

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets including bio-space and exposing our technology to different verticals. There is no assurance that the ability to produce a commercial sized biomass will result in the Company entering into commercial production of Cannabis. Clinical trials are subject to risks of significant cost overruns and lengthy delays with no assurance they will confirm desired results. Even where desired results are obtained government approvals for treatments take considerable time and cannot be guaranteed. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured. There is no assurance that the Company will be successful in acquiring a licensed facility in Canada. Health Canada approvals are required for transfers of production licenses which may take considerable time and cannot be assured. There is also no assurance that Health Canada will accept the Company's unique bioreactor production method. Production requirements in Canada are strict and require adherence to many requirements regarding safety, security and production methods and standards. Although the company is confident that its production methods will meet or exceed all standards there can be no assurance that Heath Canada will accept the Company data within a reasonable time or at all.

All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.
👍️0
happyglass happyglass 3 years ago
That explains the price drop :) they are selling the news :)
👍️0
AskMuncher AskMuncher 3 years ago
$CNVCF BioHarvest Sciences Reports Double-Digit Q4 Sales Orders Growth in First Full Year of VINIA Sales
Press Release | 01/06/2022
17% quarter-over-quarter growth with record VINIA® global sales orders in Q4 of USD 825k
485% year-over-year growth with total sales orders of USD 2.4M in 2021
Continued success in VINIA® US pilot with USD 325k in sales orders in Q4, a 27% growth over Q3
Vancouver, British Columbia, and Rehovot, Israel--(Newsfile Corp. - January 6, 2022) - BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") today announces another strong quarter of sales growth for VINIA®, its nutrient-rich red grape supplement created through the Company's proprietary BioFarming technology, in both Israel and the United States. The USD 825k of sales orders in Q4 from its direct-to-consumer ecommerce business represents a 17% increase over Q3 and are triple the sales orders from the same quarter in 2020. VINIA® sales orders in 2021 amounted to USD 2.4M, a nearly sixfold increase over 2020.

In Israel, where VINIA® is becoming synonymous with cardiovascular health and wellness, BioHarvest reported record sales orders of USD 501k in Q4, representing growth of 11% over Q3 and 84% over Q4 2020 - and total sales orders in 2021 were USD 1.73M, representing a 325% year-on-year growth.

Q4 sales orders in the ongoing US pilot program, launched in May 2021, totaled USD 325k, representing 27% growth over Q3 2021 and yielded a total sales order figure of USD 652k for the year.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6168/109227_6a045c9bd44c389a_006.jpg

VINIA® Sales Orders (USD) - by Country by Quarter Q4 2020 - Q4 2021

To view an enhanced version of this chart, please visit:
https://orders.newsfilecorp.com/files/6168/109227_6a045c9bd44c389a_006full.jpg

Moreover, sales and marketing metrics in the US point clearly to increasingly robust demand. Approximately 83% of 2020 sales and 89% of orders at www.vinia.com are derived from subscriptions packages with approximately 70% of subscriptions accounting for recurring payment packages of 3 months or more, demonstrating a significant opportunity to build a scalable, sustainable, and profitable business.

To continue to drive the company's leadership in global e-commerce and marketing, BioHarvest has hired Jared Turner as VP of Global E-Commerce. Turner, who joined in December, brings over 15 years of relevant leadership experience in building end-to-end Nutraceutical e-commerce businesses. Under his stewardship, the commercial team is poised to achieve further sales growth in VINIA® as well as other products that will be introduced in 2022, including Cannabis.

"I am very proud of the sales results achieved in the last quarter and for the entire year," said CEO, Ilan Sobel. "Combined with the scientific and technological accomplishments we posted, 2021 was an outstanding year. The sales and marketing team has demonstrated unique capabilities to successfully grow the business. We eagerly look forward to scaling our US pilot once our technology transfer to our new 20 ton/year VINIA® manufacturing facility is successfully completed, enabling us to reach optimal production levels. I anticipate another year of record sales in 2022, positively impacting the health and wellness of tens of thousands of satisfied customers."

BioHarvest further expanded the applicability of its proprietary technology in 2021, which allows it to harvest nutrients and active ingredients without growing plants, with the announcement in December that the Company had developed the capability to produce a meaningful amount - 10 kilograms - of full-spectrum Cannabis biomass without growing the plant itself.

In November, BioHarvest appointed renowned Canadian astronaut Chris Hadfield to its board of advisors as part of a drive to leverage its biotech technology platform to provide essential nutrition and active ingredients for space exploration and potential settlement in space.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Twitter
Facebook
LinkedIn
YouTube

Forward-Looking Statements

Information set forth in this news release includes forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that the Israeli market results will translate directly into the U.S. markets which may depend on different consumer preferences and more substantial marketing expenditures and resources. There is no assurance that strong sales metrics experienced to date will result in future demand or that proposed additional marketing expenditures will result in increased sales. Markets for nutraceuticals are unpredictable and subject to changes in consumer tastes and trends as well as economic factors beyond our control. There is no assurance the BioFarming technology will make a significant impact on multiple verticals of life -science based businesses in general or in the bio-space industry. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance, and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. There is no assurance that the ability to produce a commercial sized biomass will result in the Company entering into commercial production of Cannabis by H1 2022. There is no assurance of the imminent commissioning of the superfruit facility or the conversion of the two tons VINIA® facility to Cannabis production in the first half of 2022. These things are subject to construction and approval delays and uncertainties that may be beyond the control of BioHarvest. Projected sales of Cannabis will require the Company to obtain production and/or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Readers are cautioned that sales alone do not give an accurate picture of the financial position of the company and should be read in the context of the Company's annual and quarterly financial statements.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/109227
👍️0
Farmpride Farmpride 3 years ago
Very nice post. I have been happy buying into and investing in this dream. It is great to see the techknowldgy used for nutrition and wellness products indeed, that portion of the plan makes it fun to tell my friends about… now to be honest, I was first drawn in by the use for recreational THC use also, and I know this was believed out here, the idea of a more pure, consistent, various strengths and types was exciting, and produced in a first ever way … in a startup I was lucky to be part of was/is extremely exciting, especially on the verge of the world getting it straight with the “laws”.

(Deep breath) now, however this is exciting. Another biz I have found, which we my knock on the door of, I wonder if you’r not already friends with them , under the symbol CANF ? There is allot going on out here,

we all have to remember one thing going forward…we vote with out wallets! I am just hitting 66 yr. And in the last couple years i have really been focused on what I eat, when I eat, supplements, Immunity…and I bet most of us investors are in that boat, for the long haul.

.please build US a business that I / WE can pass on to our children, a famially investment as it where.. I have been in food service all my life, now so are my children… one reason I am a little glade for waiting on the recreational area is avoiding becoming a “retail lottery grab”…a meme stock. Yup I do want to see a profit , why not,..I’m not in for the next amc/bit c excetera…
and if we can’t post a dividend why not a dividend in the form of a NFT good for 50% discount on a 3 mos supply of ( take your pick)..

For now I still get excited when I check the stocks price has stayed low so I can buy some more ha, ha, but it makes my day…and please look into that one I mentioned above..that is also super cool, or can be…

Thanks much for letting me rant, maybe I’ll be using some of our products in my bakery, let me know if you have something you want tested,

Al …freezing in Wisconsin ??
👍️0
AskMuncher AskMuncher 3 years ago
$CNVCF BioHarvest Sciences Inc. 2021 CEO Letter to Shareholder Partners
Press Release | 12/30/2021
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - December 30, 2021) - BioHarvest Sciences Inc. (CSE: BHSC) (OTC PINK: CNVCF) ("BioHarvest" or the "Company") is pleased to provide the following year-end shareholder partner letter from CEO Ilan Sobel.

Dear friends,

It is with great pleasure that I take this opportunity at the end of the year to summarize for our shareholder partners the major accomplishments of what has been an inspiring and transformative first full calendar year for me as CEO of BioHarvest Sciences. I will also include my own forward-looking thoughts for how we are envisioning the year ahead, in which we expect to trigger an acceleration of revenue growth, a game-changing expansion of our product lineup, as well as regulatory work and clinical studies that will provide a clear roadmap to continued global growth. Our vision is to drive human utility value: making a fundamental and positive change to our consumer's overall health and wellness. 2022 will be a year in which we not only open new doors as we further scale and commercialize our products, but also open minds to the significant potential that our platform technology has to drive this fundamental improvement in health and wellness on a global scale.

In accordance with BioHarvest's vision and its biotech journey, I am extremely proud to share below the team's 2021 achievements grouped by key areas: Science & Technology, Operations, Sales, Finance and Environmental & Social Governance.

2021 Achievements

Science & Technology

In August 2021, we announced the historical creation of the Amalgamated Trichomes Coral Structure (ATCS). Why was this so important? Because the way to deliver full spectrum cannabis is to grow the trichomes, which are the mini factories of the cannabis plant where all cannabinoids, flavonoids and terpenes are produced. These trichomes are delicate components of the plant which can be vulnerable to the shear forces applied by the motion of the liquid media in the bioreactors. This new coral structure protects the trichomes during their growth in such a way that has enabled us to move from lab-scale creation of the trichomes towards larger scale bioreactors.
We announced on December 8 that we were the first company in the world to grow a significant amount of cannabis biomass "without growing the plant", creating biotech and Cannabis industry history. With three different strains under development, we have now produced over 10 kilograms of biomass. The news has generated significant media interest (which I will detail below), and it has also introduced our science to thousands of new investors, science fans, and cannabis enthusiasts. It has provided a firm launch point for 2022, and there is more to come: I have challenged our marketing team to have the accompanying video viewed 1 million+ times, and we are already at 250,000+, so please stay tuned to our upcoming media placements!
Through our continued research, we added a new functionality claim for VINIA®, which reduces the oxidation of LDL cholesterol, enabling VINIA® to have one more important reason to appeal to the millions of consumers concerned about their cardiovascular health.
Operations

I am so proud that our new 20 Ton per year production facility was completed on schedule, passing the ISO audits in September 2021, despite significant global supply challenges. We received GMP certification from Israel's Ministry of Health in November and we are currently working hard to execute the biological technology transfer, so we can commence production.
Our Science, Advisory and Executive teams are critical for executing our biotech vision. This year we were honored to add both significant brain power and experience to each group with the addition of Colonel Chris Hadfield (space and aeronautics), Dr. Dennis Goodman (cardiology), Steven Lehrer (biotech), and Scott McCune (consumer marketing) to our Advisory Board. David Tsur (pharmaceutical and biotech) has joined the Board of Directors. Kobi Rosenzweig (VP operations) and Jarred Turner (VP of E-commerce) have joined the executive team. Building a world class company requires world class people - I am so pleased that each of these industry experts has joined us on our journey.
Sales

Israel Sales - This time last year we were energized by the spectacular VINIA Israel ecommerce launch in Q4 2020, which established a sales momentum that we have been able to successfully maintain. Throughout 2021, we continued to grow revenue in this market, at 10% sales growth quarter on quarter, for the first 3 quarters of the year, and accordingly have increased full year guidance on two occasions.
VINIA US Market launch - May 2021. While this highlight is only one of many from 2021, it represented a giant leap forward for BioHarvest Sciences. We created entirely new operational units to facilitate the workings of a successful North American e-commerce business, including Marketing, Fulfilment, Customer Success, and global supply. We also added the required thought leadership with committed staff and external partners to bring us their expertise and drive from Launch Day forward.
Sales performance in the U.S. pilot program has been extremely encouraging with us crossing the US$100,000 sales orders per month mark very early in the launch, with 89% of sales being subscription packages generating monthly recurring revenue, and an average sales order value of US $80 per transaction.

We have been humbled by the feedback from our consumer base - as of this week, new VINIA users have submitted 350+ verified reviews, with a 4.8/5 rating, which is best in class from a performance perspective when benchmarked versus industry norms.

We look forward to scaling our US launch as soon as we bring our new 20 Ton per year manufacturing facility online and to adding significant customer count to a base that already exceeds 11,000 customers across USA and Israel.

B2B Sales - our Batory sales and distribution partnership continues to add significant value for the business. We have successfully expanded our partnership with "Designs for Health Inc" who in 2021 formulated VINIA® into 3 new products which are now commercially available including "NRF2 Modulator", "Senolytic Synergy" and "Bergavin™". We are currently engaged in a number of strategic discussions with giants of industry and look forward to converting additional major B2B partnerships in 2022.
Finance

Investors have reacted positively to the company's achievements throughout 2021. The share price increased ~130% from the beginning of the year to reflect a recently reached market capitalization of ~$200 million.
Strong treasury - In 2021, we raised a total of $9.4 Million CAD in two successful private placements, plus $4.6 Million CAD in exercised warrants.
In 2021, we have significantly increased the investor base. As the company continues to perform well against its biotech vision and increases revenues substantially, the prospects remain high for 2022 to further increase that base and to add more institutional investors.
Given the 2021 achievements record and the 2022 prospects listed below, we believe that BioHarvest presents a very attractive investment opportunity.
Environmental & Social Governance

I trust that our community of investor partners understands how deeply we are committed to making BioHarvest Sciences a role model for other companies to follow as it relates to our ESG credentials and delivering continuous improvement across key identified metrics.

In July, we became the first Biotechnology company that produces cannabinoids to publish an ESG Sustainability report. This initial report was our first, and there are more to come. As the Globe and Mail reported on Dec 28. 2021, our BioFarming technology can reduce land requirements for nutrient growth by 95%. Investors are welcome to access the complete ESG report here.
We are a company committed to diversity in the workplace and understand the power of diversity to help create competitive advantage. We are very proud of the fact that 55% of our workforce is female and that our entire R & D team is female. Importantly, as a company that understands the power of experience, we have more than 45% of our workforce above the age of 50 years old. This provides us with a wealth of brain power, people maturity and a unique sense of drive and commitment to make the world better for our children and grandchildren.
Our December media coverage on cannabis R+D has generated a wave of commercial inquiries, which is fantastic, and we are committed to responding to every contact. I want to reassure investors that we will consider every commercial opportunity, but I do want our community to understand that our first priority will be to supply cannabis ingredients for medicinal applications in line with our commitment to be a purpose driven company. We do not envision replacing recreational suppliers, or artisan growers - we will focus on providing fingerprint consistent ingredients for products that require the highest levels of cleanliness and consistency.
Media Coverage

This year, we partnered with two very established public relations firms (Boldt and Thunder-11) to help introduce us to both Major news media and the cannabis community, and it has paid huge dividends in "earned" media coverage. For the portion of our community that follows early-stage companies, this major media interest will be mind blowing, as small companies will rarely make the news cycle. Our North American news coverage is spiking here at the end of 2021, which establishes a fantastic launching point for the New Year.

Forbes.com: Dec 8 - Producing Cannabis Biomass Without Growing A Cannabis Plant - How One Company Is Doing It.
The Globe and Mail: Dec. 28 - Canadian-Israeli biotech company growing nutrients for Earth and beyond
The Houston Chronicle: Dec. 27 - Bowie Singing Astronaut developing protein pills for real space travel
CannabisTech.com: Dec. 23 - How to Grow Cannabis Without Growing a Plant
The Jerusalem Post: Dec. 29 - An astounding 2021 for Israeli tech could bring pivot
Looking Forward to 2022

This coming year will see us "land" and "expand", plus drive further impact in existing programs.

We expect to be selling our first cannabis-related products in 2022 upon completion of our final scale up phase and regulatory approvals. For VINIA, we are planning a step up in aggressive US marketing and will continue to push forward on the regulatory approval of VINIA in the EU and UK. As a science-based company, we always want to expand our science-based credentials, so we intend to fund additional clinical trials on VINIA, cannabis, and our olive cell product which is next in our polyphenol/antioxidant pipeline.

At some point in the first half of 2022, we will likely announce the next plant-based vertical which we believe we can disrupt with our proprietary platform technology, adding one more significant validation on how we can bring the power of the plant to the people. Investors can also anticipate the 2022 launch of our first cannabis products and the significant scaling of VINIA®. I expect these two products to generate market-moving revenues in 2022, but they are just the start.

We will also join the space race as the likes of Elon Musk, Jeff Bezos, and Sir Richard Branson work to make "space settlements" something of a reality by 2030. We will work closely with our new advisory board member Colonel Chris Hadfield to start the process to assess how we can use our proprietary platform to help solve two major challenges which exists for space settlements - sustainable food supply and reducing the effects of ionizing radiation on oxidation of LDL cholesterol.

Our entire team is so thankful that you have been part of this stage in our growth phase, and we are very proud to partner with you on our biotech journey. We are inspired by your support and the deep sense of "purpose" that you share with us on the BioHarvest Sciences team. That primary purpose is to drive Human Utility Value, and to drive a transformational positive change in the Health and Wellness of hundreds of millions of people.

Our team is laser focused on executing the 2022 plan, and we intend to make 2022 a year to remember.

For a video reel of this year's major announcements, click here.

Happy New Year and may your 2022 be filled with only good health and blessings.

Warmest wishes,

Ilan Sobel, Chief Executive Officer
BioHarvest Sciences Inc.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Twitter
Facebook
LinkedIn
Youtube

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets including bio-space and exposing our technology to different verticals. In particular, there is no assurance that the Company will be able to leverage its technology platform to successfully provide essential nutrition and active ingredients for space exploration. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. There is no assurance that the ability to produce a commercial sized biomass will result in the Company entering into commercial production of Cannabis. There is no assurance the Company will be able to successfully convert the exiting 2 tons/year VINIA® facility to a Cannabis production facility in H1, 2022. There is no assurance we will be able to commercialize our first Cannabis products in the first half of 2022, and there is no assurance the Company will be able to add new verticals or build additional plants elsewhere. Clinical trials are subject to risks of significant cost overruns and lengthy delays with no assurance they will confirm desired results. Even where desired results are obtained government approvals for treatments take considerable time and cannot be guaranteed. There is no assurance the BioFarming technology will make a significant impact on multiple verticals of life -science based businesses in general or in the bio-space industry. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. There is no assurance that the Israeli market results for Vinia® will translate directly into the U.S. markets which may depend on different consumer preferences and more substantial marketing expenditures and resources. There is no assurance that strong sales metrics experienced to date will result in future demand for VINIA®. Markets for nutraceuticals are unpredictable and subject to changes in consumer tastes and trends as well as economic factors beyond our control. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured.

There is no assurance we will trigger an acceleration of revenue growth or a game changing expansion of our product lineup. These things are subject to uncertainties including the uncertainty of continuing market acceptance of our products and market acceptance of new products which are subject to changing consumer preference and access to marketplaces. There is no assurance we will achieve additional major B2B partnerships in 2022 as this is subject to acceptance of our products by businesses and their customers. There is no assurance that we will increase our investor base or add new institutional investors as this is subject to our meeting investment criteria of investors and conditions affecting equity markets generally. Continuing outbreaks of Covid variants may cause delays or other impacts to business plans and /or impact equity markets in 2022.

All forward-looking statements are inherently uncertain, and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.
👍️0
happyglass happyglass 3 years ago
I do not know if this has been posted here yet
https://www.cannabistech.com/articles/how-to-grow-cannabis-without-growing-a-plant/?fbclid=IwAR2HUOqoNrTJPyuBneNYY4VVCWMzbFt5KT1XuFShOqz3pCzC9pExjda0GuY
👍️0
happyglass happyglass 3 years ago
I vote with my dollar for a better world. If I do not help people with a good idea make it happen who will? That is the reason I am so focused on the cannabis sector is that this stuff is such a healing medicine that has been used as food and wellbeing for aeons and it was made “ illegal” for the benefit of chemical companies and timber barons. This grows more paper per acre faster than timber does. It cures many things including intractable epilepsy in children and the govt still treats it like a toxin! Even though there has never been a death attributed to this plant. The only way it changes is if we common folks make it happen! I will take a look at your suggestion. Cannabis is a food, a medicine and a fibre. There is a canadian man named Rick Simpson who cured cancer in people who were sent home to die by the medical systems (I am not anti doctor!) and fir his trouble he was harassed by the rcmp to the point he left and now lives in exile! They took his records and now lo and behold we have a bunch of ex police in line at the money trough. We need research, and investment in wellbeing that comes from natural sources and this project is a hybrid. Purity is needed when people rely on a medicine and this seems to fit the bill. Outdoor grown has many qualities but it can have molds and such that are hard to manage. Pesticides do not work, because it is used “raw”, you can not heat it without changing it and you can not wash it because it knocks off the active ingredient, the trichomes. This system seems to solve those problems and it may be able to produce rare cannabanoids at scale such exciting times ahead.
👍️0
Farmpride Farmpride 3 years ago
My last post has a mistake..I mentioned a (Phpi), should be ..PHBI…??

Al..happy hunting.
👍️0
Farmpride Farmpride 3 years ago
The only thing I have found that comes close in the ag space, and is adaptable to ,”not only hemp/mj” is PHPI. (Talking high tech and highly focused).. it’s all really wild what’s going on really. The whole agriculture space is changing and much is doable for the smallest of us to the biggies of us :) every one of us needs to start growing “anything”, and investing in the best entrepreneurs we can find…not just the next 100 x-er we can hit and run on! Steady long term companies need some steady long term investors… ha…my Pennie’s worth??

Al.
👍️0
happyglass happyglass 3 years ago
I have been in the legal cannabis space since 2015. This is a game changer. I love the fact they are already producing the red grape products (I want to get some of that too!) but cannabis is the next “big thing”. I am very familiar with the challenges of growing at scale and it is challenging to say the least and achievable by very few. This will provide the clean and consistent input for nutraceuticals and CPG products. So excited because this medicine is incredible and we need more of it in the world. Such an exciting time to be alive!
👍️0
Farmpride Farmpride 3 years ago
My fav. Holding...to me this is the sleeper of the decade. It is one of those overnight sensations now years in the making..;)
👍️0
AskMuncher AskMuncher 3 years ago
$CNVCF BioHarvest Sciences Inc. Announces Appointment of David Tsur to Board of Directors
Press Release | 10/21/2021
David Tsur's 40 years of Biotech experience further strengthens the Board at a critical phase of the Company's growth
His appointment reinforces the Company's primary focus on becoming a Biotech leader, leveraging the power of its platform technology to disrupt multiple business verticals
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 21, 2021) - BioHarvest Sciences Inc. (CSE: BHSC) (FSE: 8MV) ("BioHarvest" or the "Company") today announced that David Tsur has agreed to serve as a non-executive director of BioHarvest. The appointment is effective immediately.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6168/100441_06b50bfd24fbb94f_006.jpg

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6168/100441_06b50bfd24fbb94f_006full.jpg

"We are excited to welcome David to Bioharvest's board," said Dr. Zaki Rakib, Chairman of the Board. "BioHarvest is committed to world-class governance, and our ability to attract someone of David's caliber demonstrates the strength of our business."

David Tsur said: "I am very excited to join the Board of BioHarvest. I truly believe that BioHarvest's proprietary BioFarming technology will revolutionise a number of industries, and I look forward to working with the Board and management to fully operationalise this vision."

Ilan Sobel, CEO of BioHarvest, commented: "David is an important addition to the Board as we look to deliver against the Company's strategic objectives. Most importantly, David joining the Board is a testament to our ability to attract highly qualified individuals to join our team. I have spent significant time already with David and am confident he will play a key role in helping myself and the leadership team deliver on our Biotech Vision for the Company."

The Board has granted Mr. Tsur 400,000 options. The stock options granted are exercisable to purchase a common share of the Company at a price of CAD$ 0.345 and will vest quarterly over a 3-year period and are valid for 10 years.

DETAILED BIOGRAPHY

Mr. Tsur is the co-founder of Kamada Ltd, a public company listed on both the NASDAQ and Tel-Aviv Stock Exchange. He served as its Chief Executive Officer and on its Board of directors since the Company's inception in 1990. He currently serves as Deputy Chairman of the Board.

He also serves as the Chairman of Kanabo Group Plc, a company listed on the London Stock Exchange, which focuses on distributing Cannabis-derived products for medical patients and non-THC products for CBD consumers.

Before co-founding Kamada, Mr. Tsur was the Chief Executive Officer of Arad Systems and RAD Chemicals Inc. He has also held various positions in the Israeli Ministry of Economy (formerly named the Ministry of Industry and Trade), including Chief Economist and Commercial Attaché in Argentina and Iran.

During his career, Mr. Tsur has been responsible for generating sales of more than $1 billion (USD) for companies operating in more than 20 countries. He has also built multiple strategic relationships with U.S. and European companies while leading these companies through the innovation processes.

Mr. Tsur holds a BA degree in Economics and International Relations and an MBA in Business Management from the Hebrew University of Jerusalem.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Twitter
Facebook
LinkedIn
YouTube

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets and exposing our technology to different verticals. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. Clinical trials are subject to risks of significant cost overruns and lengthy delays with no assurance they will confirm desired results. Even where desired results are obtained government approvals for treatments take considerable time and cannot be guaranteed. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and / or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/100441

👍️0
AskMuncher AskMuncher 3 years ago
$CNVCF BioHarvest Sciences Inc. Increases Its VINIA 2021 Annual Sales Orders Forecast for Israel by 15%
Press Release | 10/13/2021
Vancouver, Canada, and Rehovot, Israel--(Newsfile Corp. - October 13, 2021) - BioHarvest Sciences Inc. (CSE: BHSC) (FSE: 8MV) ("BioHarvest" or the "Company") today announces an update to its forecast of 2021 annual sales orders for VINIA® in Israel. The Company has increased its 2021 sales orders forecast for Israel to US$ 1.6M - US$ 1.7M from the previous forecast of US$ 1.3M - US$ 1.5M announced in March 2021.

The continued adoption of VINIA® in Israel demonstrates the health benefits and efficacy of the product. The high percentage of revenue from returning customers validate their loyalty to the product. The combination of increased transactions and the increased value of each order is fueling revenue growth. Next January, the company will provide a sales orders forecast calendar for the year 2022.

Ilan Sobel, the CEO, said: "The 15% increase in the Company's forecast is a testimonial to the quality and efficacy of VINIA® and to its ability to reach customers. We are constantly improving our methods to reach out to customers and build a strong base of loyal consumers. I look forward to the continued growth in sales orders and to bringing new products to the market in 2022."

Q3 Shareholder Update

We invite all interested investors and media to our next Shareholder Update, to be held at 11am PST, October 14, 2021. The online meeting will be hosted by the CEO, Ilan Sobel, and will feature a live Question and Answer session. If you are not available to attend live, please register and we can send you the session recording after the event. Register at: https://app.livestorm.co/st-financial/october-2021-bhsc-shareholder-update?type=detailed

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6168/99472_13c5b964c438780c_007full.jpg

Register Now

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6168/99472_13c5b964c438780c_007full.jpg

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Twitter
Facebook
LinkedIn
YouTube

Forward-Looking Statements

Information set forth in this news release includes forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that the Israeli market results will translate directly into the U.S. markets which may depend on different consumer preferences and more substantial marketing expenditures and resources. There is no assurance that strong sales metrics experienced to date will result in future demand or that the 15% increase for VINIA® sales orders forecast in Israel will be achieved by end of 2021. Markets for nutraceuticals are unpredictable and subject to changes in consumer tastes and trends as well as economic factors beyond our control. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance, and regulatory approvals for geographic expansion is subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the Company to obtain production and/or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99472
👍️0
Augustwd Augustwd 4 years ago
Thank you Renee
👍️0
Renee Renee 4 years ago
Canna-V-Cell Sciences Inc. changed to Bioharvest Sciences Inc.:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
👍️0

Your Recent History

Delayed Upgrade Clock